Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Europe save search
Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
Published: 2023-02-08 (Crawled : 14:20) - biospace.com/
ATRA | $0.7101 -1.18% -1.2% 700K
|
Health Technology
|
| O: 0.0%
H: 0.89%
C: -7.69%
europe immunotherapy transfer t-cell approved authorization
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Published: 2023-01-17 (Crawled : 11:00) - biospace.com/
RLFTF | $1.45 11.45% 1.3K
|
n/a
|
| O: -8.26%
H: 14.0%
C: 10.0%
td011 treatment t-cell trial approval therapeutics
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Published: 2022-09-16 (Crawled : 12:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.12%
H: 1.31%
C: 0.8%
yescarta europe chmp t-cell positive therapy
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
AUTL | $4.23 -5.58% -5.91% 2.7M
|
Health Technology
|
| O: 1.17%
H: 3.47%
C: 1.73%
treatment fda designation therapy rmat
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma
Published: 2021-12-07 (Crawled : 15:00) - biospace.com/
VINC | $0.9392 -1.14% -1.15% 460K
|
|
| O: 8.68%
H: 8.37%
C: 3.66%
treatment europe drug orphan drug t-cell designation pharma
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Published: 2021-11-22 (Crawled : 13:30) - globenewswire.com
TOMDF | $0.0001 100.0% 14M
|
Manufacturing
|
| O: -5.56%
H: 15.29%
C: 8.24%
europe order distribution t-cell
Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cellsTetracycline and minocycline controllable CAR T cell system to manage toxicities
Published: 2021-11-10 (Crawled : 21:00) - biospace.com/
AUTL | $4.23 -5.58% -5.91% 2.7M
|
Health Technology
|
| O: -4.3%
H: 8.02%
C: 0.81%
car-t t-cell
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2021-10-13 (Crawled : 13:15) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.27%
H: 2.38%
C: 1.07%
t-cell
LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 21:00) - biospace.com/
LVTX | $2.77 -7.05% -7.58% 150K
|
|
| O: -3.3%
H: 5.92%
C: 0.77%
treatment molecular cancer conference t-cell
F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021Preclinical Data Indicates a Broad Therapeutic Window for F-star’s First-in-Class Tetravalent Dual T cell Agonist
Published: 2021-09-16 (Crawled : 13:15) - biospace.com/
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: -0.28%
H: 0.71%
C: -0.43%
phase 1 trial t-cell
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-08-26 (Crawled : 21:00) - biospace.com/
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 0.28%
H: 0.89%
C: -2.02%
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: -0.49%
H: 1.34%
C: -0.42%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.25%
H: 0.33%
C: -1.05%
treatment europe approval t-cell
Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma
Published: 2021-08-19 (Crawled : 16:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.41%
H: 2.16%
C: 1.27%
europe therapy approval car-t t-cell
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-06-25 (Crawled : 12:15) - biospace.com/
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 0.06%
H: 2.35%
C: 0.75%
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 2.89%
H: 0.23%
C: -0.55%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.71%
H: 1.74%
C: 1.53%
treatment positive chmp t-cell
Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
AUTL | $4.23 -5.58% -5.91% 2.7M
|
Health Technology
|
| O: 3.65%
H: 13.94%
C: 8.87%
europe cel t-cell
Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at the European Hematology Association Virtual Congress
Published: 2021-05-12 (Crawled : 14:15) - globenewswire.com
AUTL | $4.23 -5.58% -5.91% 2.7M
|
Health Technology
|
| O: -2.0%
H: 42.74%
C: 38.24%
europe t-cell
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses
Published: 2021-04-27 (Crawled : 14:00) - biospace.com/
PKI | $115.24 0.0% 1.6M
|
Health Technology
|
| O: 0.34%
H: 0.32%
C: -0.32%
covid ford test vaccine trial sars-cov-2 t-cell
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.